Is INMB or SPRB more profitable?

INmune Bio's return on equity of -103.03% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Spruce Biosciences N/A -155.40% -101.67%

Does the media favor INMB or SPRB?

In the previous week, INmune Bio had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for INmune Bio and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.94 beat INmune Bio's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INMB or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Enlivex Therapeutics N/A 248.08% 206.39%

Is INMB or CGTX more profitable?

Cognition Therapeutics' return on equity of -72.68% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets INmune Bio N/A -103.03% -77.66% Cognition Therapeutics N/A -72.68% -53.07%

Does the media prefer INMB or CGTX?

In the previous week, INmune Bio and INmune Bio both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 0.78 beat INmune Bio's score of 0.62 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TLSA or INMB?

INmune Bio has a consensus price target of $8.00, indicating a potential upside of 369.21%. Given INmune Bio's stronger consensus rating and higher possible upside, analysts clearly believe INmune Bio is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has stronger earnings & valuation, TLSA or INMB?

Tiziana Life Sciences has higher earnings, but lower revenue than INmune Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A INmune Bio $50K 906.38 -$45.93M -$1.67 N/A

Is TLSA or INMB more profitable?

Tiziana Life Sciences' return on equity of 0.00% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A INmune Bio N/A -103.03% -77.66%

Does the media favor TLSA or INMB?

In the previous week, INmune Bio had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for INmune Bio and 3 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.63 beat INmune Bio's score of 0.62 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INMB or ADCT?

In the previous week, ADC Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 5 mentions for ADC Therapeutics and 4 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.10 indicating that INmune Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

INmune Bio (INMB) Competitors

$1.70 +0.08 (+4.60%)

As of 11:17 AM Eastern

Compare

INMB vs. SPRB, ENLV, CGTX, TLSA, and ADCT

Should you buy INmune Bio stock or one of its competitors? MarketBeat compares INmune Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with INmune Bio include Spruce Biosciences (SPRB), Enlivex Therapeutics (ENLV), Cognition Therapeutics (CGTX), Tiziana Life Sciences (TLSA), and ADC Therapeutics (ADCT). These companies are all part of the "pharmaceutical products" industry.

How does INmune Bio compare to Spruce Biosciences?

INmune Bio (NASDAQ:INMB) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

INmune Bio currently has a consensus target price of $8.00, indicating a potential upside of 369.21%. Spruce Biosciences has a consensus target price of $163.00, indicating a potential upside of 203.53%. Given INmune Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe INmune Bio is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, INmune Bio had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 4 mentions for INmune Bio and 2 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.94 beat INmune Bio's score of 0.62 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

INmune Bio has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, indicating that its share price is 211% more volatile than the broader market.

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 21.4% of INmune Bio shares are held by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Spruce Biosciences has higher revenue and earnings than INmune Bio. Spruce Biosciences is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	906.38	-$45.93M	-$1.67	N/A
Spruce Biosciences	$4.91M	30.08	-$38.97M	-$36.60	N/A

INmune Bio's return on equity of -103.03% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Spruce Biosciences	N/A	-155.40%	-101.67%

Summary

INmune Bio beats Spruce Biosciences on 10 of the 16 factors compared between the two stocks.

How does INmune Bio compare to Enlivex Therapeutics?

INmune Bio (NASDAQ:INMB) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, INmune Bio had 3 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 4 mentions for INmune Bio and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.93 beat INmune Bio's score of 0.62 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
INmune Bio	Positive
Enlivex Therapeutics	Positive

Enlivex Therapeutics has lower revenue, but higher earnings than INmune Bio. INmune Bio is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	906.38	-$45.93M	-$1.67	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

INmune Bio currently has a consensus target price of $8.00, suggesting a potential upside of 369.21%. Enlivex Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 3,001.50%. Given Enlivex Therapeutics' higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics' return on equity of 248.08% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Enlivex Therapeutics	N/A	248.08%	206.39%

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

INmune Bio has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, indicating that its stock price is 47% more volatile than the broader market.

Summary

Enlivex Therapeutics beats INmune Bio on 8 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Cognition Therapeutics?

INmune Bio (NASDAQ:INMB) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Cognition Therapeutics has lower revenue, but higher earnings than INmune Bio. Cognition Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	906.38	-$45.93M	-$1.67	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

In the previous week, INmune Bio and INmune Bio both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 0.78 beat INmune Bio's score of 0.62 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

12.7% of INmune Bio shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 21.4% of INmune Bio shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

INmune Bio presently has a consensus target price of $8.00, indicating a potential upside of 369.21%. Cognition Therapeutics has a consensus target price of $3.33, indicating a potential upside of 196.30%. Given INmune Bio's stronger consensus rating and higher possible upside, research analysts plainly believe INmune Bio is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

INmune Bio has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Cognition Therapeutics' return on equity of -72.68% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Summary

Cognition Therapeutics beats INmune Bio on 8 of the 14 factors compared between the two stocks.

How does INmune Bio compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Tiziana Life Sciences has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, INmune Bio has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Tiziana Life Sciences' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
INmune Bio	N/A	-103.03%	-77.66%

Tiziana Life Sciences has higher earnings, but lower revenue than INmune Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
INmune Bio	$50K	906.38	-$45.93M	-$1.67	N/A

In the previous week, INmune Bio had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for INmune Bio and 3 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 0.63 beat INmune Bio's score of 0.62 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

INmune Bio has a consensus price target of $8.00, indicating a potential upside of 369.21%. Given INmune Bio's stronger consensus rating and higher possible upside, analysts clearly believe INmune Bio is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

12.7% of INmune Bio shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by company insiders. Comparatively, 21.4% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

INmune Bio beats Tiziana Life Sciences on 8 of the 13 factors compared between the two stocks.

How does INmune Bio compare to ADC Therapeutics?

INmune Bio (NASDAQ:INMB) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

INmune Bio has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	$50K	906.38	-$45.93M	-$1.67	N/A
ADC Therapeutics	$81.36M	1.79	-$142.62M	-$1.05	N/A

In the previous week, ADC Therapeutics had 1 more articles in the media than INmune Bio. MarketBeat recorded 5 mentions for ADC Therapeutics and 4 mentions for INmune Bio. INmune Bio's average media sentiment score of 0.62 beat ADC Therapeutics' score of 0.10 indicating that INmune Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
INmune Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

INmune Bio currently has a consensus price target of $8.00, suggesting a potential upside of 369.21%. ADC Therapeutics has a consensus price target of $6.25, suggesting a potential upside of 445.85%. Given ADC Therapeutics' higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

INmune Bio has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

INmune Bio has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-103.03%	-77.66%
ADC Therapeutics	-173.02%	N/A	-44.70%

12.7% of INmune Bio shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 21.4% of INmune Bio shares are held by insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ADC Therapeutics beats INmune Bio on 9 of the 17 factors compared between the two stocks.

Get INmune Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INMB vs. The Competition

Export

Metric	INmune Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$44.79M	$3.66B	$6.81B	$12.57B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-1.01	21.44	27.52	25.33
Price / Sales	906.38	339.00	539.41	102.00
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	1.94	8.75	10.94	6.61
Net Income	-$45.93M	$23.87M	$3.57B	$336.72M
7 Day Performance	26.30%	3.51%	2.69%	2.63%
1 Month Performance	22.66%	3.56%	1.84%	0.24%
1 Year Performance	-18.42%	67.21%	36.35%	29.97%

INmune Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INMB INmune Bio	1.7731 of 5 stars	$1.71 +4.6%	$8.00 +369.2%	-29.4%	$44.79M	$50K	N/A	10	News Coverage
SPRB Spruce Biosciences	2.844 of 5 stars	$53.19 -2.8%	$163.00 +206.4%	+893.1%	$146.84M	N/A	N/A	20
ENLV Enlivex Therapeutics	3.3762 of 5 stars	$0.63 +0.6%	$16.50 +2,531.6%	-50.9%	$145.51M	N/A	N/A	70	Gap Up
CGTX Cognition Therapeutics	3.7508 of 5 stars	$1.61 -4.3%	$3.33 +107.4%	+271.2%	$143.83M	N/A	N/A	20	Gap Up
TLSA Tiziana Life Sciences	0.5054 of 5 stars	$1.10 -4.3%	N/A	-19.0%	$139.99M	N/A	N/A	8

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INMB) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

INmune Bio (INMB) Competitors

INMB vs. SPRB, ENLV, CGTX, TLSA, and ADCT

How does INmune Bio compare to Spruce Biosciences?

Summary

How does INmune Bio compare to Enlivex Therapeutics?

Summary

How does INmune Bio compare to Cognition Therapeutics?

Summary

How does INmune Bio compare to Tiziana Life Sciences?

Summary

How does INmune Bio compare to ADC Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

INmune Bio (INMB) Competitors

INMB vs. SPRB, ENLV, CGTX, TLSA, and ADCT

How does INmune Bio compare to Spruce Biosciences?

Do analysts rate INMB or SPRB?

Does the media favor INMB or SPRB?

Which has more risk and volatility, INMB or SPRB?

Do insiders & institutionals believe in INMB or SPRB?

Which has stronger earnings & valuation, INMB or SPRB?

Is INMB or SPRB more profitable?

Summary

How does INmune Bio compare to Enlivex Therapeutics?

Does the media favor INMB or ENLV?

Which has higher earnings & valuation, INMB or ENLV?

Do analysts recommend INMB or ENLV?

Is INMB or ENLV more profitable?

Do insiders & institutionals believe in INMB or ENLV?

Which has more risk and volatility, INMB or ENLV?

Summary

How does INmune Bio compare to Cognition Therapeutics?

Which has stronger earnings and valuation, INMB or CGTX?

Does the media prefer INMB or CGTX?

Do institutionals & insiders believe in INMB or CGTX?

Do analysts rate INMB or CGTX?

Which has more volatility & risk, INMB or CGTX?

Is INMB or CGTX more profitable?

Summary

How does INmune Bio compare to Tiziana Life Sciences?

Which has more volatility and risk, TLSA or INMB?

Is TLSA or INMB more profitable?

Which has stronger earnings & valuation, TLSA or INMB?

Does the media favor TLSA or INMB?

Do analysts prefer TLSA or INMB?

Do institutionals & insiders have more ownership in TLSA or INMB?

Summary

How does INmune Bio compare to ADC Therapeutics?

Which has stronger valuation and earnings, INMB or ADCT?

Does the media prefer INMB or ADCT?

Do analysts rate INMB or ADCT?

Which has more volatility & risk, INMB or ADCT?

Is INMB or ADCT more profitable?

Do insiders and institutionals hold more shares of INMB or ADCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB vs. The Competition

INmune Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools